Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial
Rufino Silva, Luis Arias, Sandrina Nunes, Claudia Farinha, Rita Coimbra, João P Marques, Maria L Cachulo, João Figueira, Patricia Barreto, Maria H Madeira, Isabel Pires, João C Sousa, Laura Distefano, Paulo Rosa, Ângela Carneiro, Sara Vaz-Pereira, Angelina Meireles, Francisco Cabrera, Anniken Bures, Luís Mendonça, Alvaro Fernandez-Vega-Sanz, Sandra Barrão, Adrian Koh, Chui Ming Gemmy Cheung, José G Cunha-Vaz, Joaquim Murta, EVICR.net ATLANTIC Study Group, Rufino Silva, Luis Arias, Sandrina Nunes, Claudia Farinha, Rita Coimbra, João P Marques, Maria L Cachulo, João Figueira, Patricia Barreto, Maria H Madeira, Isabel Pires, João C Sousa, Laura Distefano, Paulo Rosa, Ângela Carneiro, Sara Vaz-Pereira, Angelina Meireles, Francisco Cabrera, Anniken Bures, Luís Mendonça, Alvaro Fernandez-Vega-Sanz, Sandra Barrão, Adrian Koh, Chui Ming Gemmy Cheung, José G Cunha-Vaz, Joaquim Murta, EVICR.net ATLANTIC Study Group
Abstract
Importance: Polypoidal choroidal vasculopathy (PCV) is far less common and studied in a Caucasian population than in an Asian population, and the optimal treatment approach remains to be confirmed.
Methods: A 52-week, double-masked, sham-controlled, phase 4, investigator-initiated randomized clinical trial (RCT) in naive symptomatic Caucasian patients with PCV treated with aflibercept in a treat-and-extend regimen (T&E) (intravitreal aflibercept injection [IVAI] T&E). Patients were randomized at week 16 to receive IVAI T&E plus either sham photodynamic therapy (PDT) or standard fluence PDT with verteporfin. The main outcome measures were changes in best-corrected visual acuity (BCVA) from baseline to 52 weeks and polyp occlusion at week 52. Data are presented as median (interquartile range [IQR]) for BCVA, number of IVAI, and change in central retinal thickness (CRT).
Results: Of the 50 patients included in the study, 48 patients completed the 52 weeks of follow-up. During this period, a significant median (IQR) BCVA gain of 6 [2-12] Early Treatment Diabetic Retinopathy Study letters was observed for all patients (p < 0.001), after 8 (7-9) injections, with a significant reduction of -93.0 [-154.0, -44.0] µm in central macular thickness (p < 0.001). Using indocyanine green angiography, a complete occlusion of polypoidal lesions was documented in 72% of the cases. Still, no significant difference was detected between the sham PDT and the aflibercept PDT arms, at week 52, for BCVA change (6.5 [2-11] vs. 5 [2-13] letters (p = 0.98)), number of IVAIs (8.5 [7-9] vs. 8 [7-9] (p = 0.21)), change in CRT (-143 [-184; -47] vs. -89 [-123; -41.5] µm [p = 0.23]), and rates of complete polyp occlusion: 77 versus 68% (p = 0.53) or presence of fluid: 68 versus 57% (p = 0.56). No serious ocular adverse events were registered in the 2 arms.
Conclusions and relevance: To our knowledge, this is the first RCT to compare aflibercept T&E monotherapy with aflibercept T&E plus verteporfin PDT in a Caucasian population with PCV. Aflibercept monotherapy in a T&E showed to be effective and safe with a significant median BCVA improvement of 6 letters and a complete occlusion of polypoidal lesions in near 3 quarters of the eyes, at 1 year. As only 22% of the eyes underwent PDT treatment, the benefit of combined treatment for PCV in Caucasian patients could not be definitively elucidated from this study.
Trial registration: The clinical trial was registered in ClinicalTrials.gov Identifier NCT02495181 and the European Union Drug Regulating Authorities Clinical Trials Database EudraCT No. 2015-001368-20.
Keywords: Aflibercept; Efficacy; Monotherapy; Photodynamic therapy; Polypoidal choroidal vasculopathy.
© 2021 The Author(s) Published by S. Karger AG, Basel.
Source: PubMed